A5001293261- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Inflammatory mediators and NSAID effects
- Peptidase Inhibition and Analysis
- Neuroscience and Neuropharmacology Research
- Epilepsy research and treatment
- Cytokine Signaling Pathways and Interactions
- Cancer Research and Treatments
- Ion channel regulation and function
- Sleep and related disorders
- Circadian rhythm and melatonin
- Biosimilars and Bioanalytical Methods
- Autoimmune Bullous Skin Diseases
- Sleep and Wakefulness Research
- Pharmacological Receptor Mechanisms and Effects
- Cancer, Stress, Anesthesia, and Immune Response
- CAR-T cell therapy research
- Complement system in diseases
- Urticaria and Related Conditions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Radiopharmaceutical Chemistry and Applications
- Pharmacological Effects and Toxicity Studies
- Multiple Myeloma Research and Treatments
- Receptor Mechanisms and Signaling
- Pharmacogenetics and Drug Metabolism
Roche (Switzerland)
2021-2024
Idorsia (Switzerland)
2019-2022
Centre Hospitalier Universitaire de Bordeaux
2020
Laboratoires M. Richard (France)
1991
Abstract Purpose: In this study, we report the results from esophageal squamous cell carcinoma (SCC) cohort of a phase II, noncomparative, basket study evaluating antitumor activity and safety fibroblast activation protein–IL2 variant (FAP-IL2v) plus atezolizumab in patients with advanced/metastatic solid tumors (NCT03386721). Patients Methods: Eligible had an Eastern Cooperative Oncology Group performance status 0 to 1; measurable metastatic, persistent, or recurrent SCC; progression on ≥1...
5510 Background: Simlukafusp alfa (SIM; FAP-IL2v) comprises an interleukin-2 variant (IL-2v) moiety and antibody against fibroblast activation protein-α (FAP). The binding of SIM to FAP, expressed on cancer-associated fibroblasts, accounts for retention accumulation in malignant lesions. engineered IL-2v has abolished IL-2Rα while the affinity IL-2Rβγ is retained, resulting immune effector CD8 T NK cells, but not regulatory therefore may augment activity PD-(L)1 inhibitors. Methods: clinical...
Summary Objective Increased activity of T‐type Ca 2+ channels is linked to idiopathic generalized epilepsies, thus blocking these may be a new treatment option. ACT ‐709478 an orally available triple channel blocker. The aim this first‐in‐man study was investigate the pharmacokinetics, pharmacodynamics, tolerability, and safety single doses in healthy subjects. Methods This double‐blind, placebo‐controlled, randomized included 65 male Ascending oral 1‐400 mg or placebo were administered...
Aberrantly controlled activation of the complement system contributes to inflammatory diseases. Safety, tolerability, and pharmacokinetics single-ascending doses ACT-1014-6470, a novel orally available factor 5a receptor 1 antagonist, were assessed in randomized, double-blind, placebo-controlled Phase study. Six ACT-1014-6470 (0.5-200 mg) selected after predictions from Complex Dedrick plot. In each group, or matching placebo was administered six two healthy male individuals under fed...
<p>Biomarker analyses and association with clinical outcomes</p>
<p>Eligibility criteria and additional study design assessments</p>
<p>Biomarker analyses and association with clinical outcomes</p>
<p>Class-specific adverse events</p>
<p>Pharmacodynamic analyses of peripheral blood</p>
<p>Class-specific adverse events</p>
<div>AbstractPurpose:<p>In this study, we report the results from esophageal squamous cell carcinoma (SCC) cohort of a phase II, noncomparative, basket study evaluating antitumor activity and safety fibroblast activation protein–IL2 variant (FAP-IL2v) plus atezolizumab in patients with advanced/metastatic solid tumors (NCT03386721).</p>Patients Methods:<p>Eligible had an Eastern Cooperative Oncology Group performance status 0 to 1; measurable metastatic, persistent,...
<div>AbstractPurpose:<p>In this study, we report the results from esophageal squamous cell carcinoma (SCC) cohort of a phase II, noncomparative, basket study evaluating antitumor activity and safety fibroblast activation protein–IL2 variant (FAP-IL2v) plus atezolizumab in patients with advanced/metastatic solid tumors (NCT03386721).</p>Patients Methods:<p>Eligible had an Eastern Cooperative Oncology Group performance status 0 to 1; measurable metastatic, persistent,...
<p>Pharmacodynamic analyses of peripheral blood</p>
<p>Eligibility criteria and additional study design assessments</p>